Chris C. Parker
London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.
Overview
Chris Parker is a clinical oncologist at The Royal Marsden and The Institute of Cancer Research. He was first author of the 2013 New England Journal of Medicine report of ALSYMPCA, in which the alpha-emitter radium-223 improved overall survival in castration-resistant prostate cancer with bone metastases, and of the 2020 Lancet report of RADICALS-RT, which found that early salvage radiotherapy on PSA rise was as good as adjuvant radiotherapy after prostatectomy, with less toxicity.
| Title | Journal | Year |
|---|---|---|
| ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases | New England Journal of Medicine | 2013 |
| RADICALS-RT: timing of radiotherapy after radical prostatectomy | The Lancet | 2020 |
Similar pages
not linked directly; found by shared links- PersonA. Oliver Sartor
Shares Radium-223, Prostate cancer and the tags prostate, trialist.
- TrialALSYMPCA
Shares ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases, Radium-223, Metastatic castration-resistant prostate cancer, Prostate cancer.
- PersonKarim Fizazi
Shares Radium-223 with abiraterone: a caution, not a combination, Radium-223, Prostate cancer.
- OpportunityGRPR imaging when the PSMA scan is negative
Shares Biochemical recurrence of prostate cancer, Metastatic castration-resistant prostate cancer and the tag prostate.
- AgentAbiraterone acetate
Shares The Royal Marsden, Radium-223 with abiraterone: a caution, not a combination, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- AgentOlaparib
Shares The Royal Marsden, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares Biochemical recurrence of prostate cancer, Prostate cancer.